The public stock history of AstraZeneca traces back to the major 1999 corporate merger between Sweden-based Astra AB and the United Kingdom-based Zeneca Group. Since its formation, the company's equity has experienced substantial long-term growth driven by blockbuster drug commercialization, strategic biotechnology acquisitions, and continuous research investments. Over the decades, its shares have navigated various macroeconomic cycles, patent cliffs, and health crises, maintaining a prominent position on major global stock exchanges.